Prazosin Hcl Tablets Suppliers & Bulk Manufacturers
Available Forms: Extended-release (ER) tablets
Available Strengths: 1 mg, 2 mg, 5 mg,10 mg
Reference Brands: Alpress LP
Category:
Drugs Using Osmotic Pump Systems
Alpress LP® (prazosin HCl) is an alpha-1 adrenergic blocker that relaxes blood vessels and prostate smooth muscle, reducing blood pressure and urinary symptoms. Benefits include improved urinary flow in BPH, lower BP, symptom relief, and better quality of life when used as prescribed.
Prazosin HCl tablets is available in Extended-release (ER) tablets
and strengths such as 1 mg, 2 mg, 5 mg,10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Prazosin HCl tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Prazosin HCl tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Alpress LP® (prazosin HCl) is regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality in compliance with GMP standards. In the US, FDA approval involved clinical validation and safety assessments; in the EU, CE marking certifies conformity with MDR standards. These formulations undergo validation, stability testing, and audits, with comprehensive documentation including safety profiles, clinical data, and manufacturing practices.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing